[ad_1]
Biogen CEO Michel Vounatsos acknowledged Monday that the corporate was “improper” to cost its Alzheimer’s illness remedy Aduhelm at $56,000 a 12 months, however added that its determination to later slash the fee practically in half was “brave.”
Talking nearly on the J.P. Morgan Healthcare Convention, Vounatsos described the corporate’s flagging income and the disastrous launch of Aduhem as “near-term challenges [that] usually are not defining Biogen,” and harassed “the corporate’s fundamentals are very sturdy.”
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
What’s it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, coverage, and life science protection and evaluation.
Our award-winning staff covers information on Wall Avenue, coverage developments in Washington, early science breakthroughs and medical trial outcomes, and well being care disruption in Silicon Valley and past.
What’s included?
- Every day reporting and evaluation
- Probably the most complete trade protection from a powerhouse staff of reporters
- Subscriber-only newsletters
- Every day newsletters to transient you on a very powerful trade information of the day
- STAT+ Conversations
- Weekly alternatives to interact with our reporters and main trade consultants in stay video conversations
- Unique trade occasions
- Premium entry to subscriber-only networking occasions across the nation
- The most effective reporters within the trade
- Probably the most trusted and well-connected newsroom within the well being care trade
- And far more
- Unique interviews with trade leaders, profiles, and premium instruments, like our CRISPR Trackr.
[ad_2]
Source link
